Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases

Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastases (BM) remains unknown. EGFR mutation status were collected from 1560 patients with NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guowei, Cheng, Ruirui, Zhang, Zengli, Jiang, Tao, Ren, Shengxiang, Ma, Zhiyong, Zhao, Sha, Zhou, Caicun, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314405/
https://www.ncbi.nlm.nih.gov/pubmed/28211502
http://dx.doi.org/10.1038/srep42979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314405/
https://www.ncbi.nlm.nih.gov/pubmed/28211502
http://dx.doi.org/10.1038/srep42979

Ejemplares similares